{
    "name": "eflapegrastim",
    "comment": "Rx",
    "other_names": [
        "Rolvedon",
        "eflapegrastim-xnst"
    ],
    "classes": [
        "Hematopoietic Growth Factors"
    ],
    "source": "https://reference.medscape.com/drug/rolvedon-eflapegrastim-4000053",
    "pregnancy": {
        "common": [
            "Data are not available regarding use in pregnant females; however, data from published studies with use of other rhG-CSF products during pregnancy have not identified any drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Reproductive studies were conducted in rats and rabbits",
                    "In rats, eflapegrastim did not adversely affect embryofetal and/or postnatal development when administered from organogenesis throughout lactation at doses that produced maternal exposures up to 7x the exposure at recommended clinical dose",
                    "In rabbits, eflapegrastim caused embryofetal lethality and reduced fetal weight when administered during organogenesis at approximately 6x the exposure at the clinical dose"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are not available regarding presence in human milk, effects on breastfed children, or effects on milk production",
            "Endogenous G-CSF is present in human milk; other rhG-CSF products are present in human milk at low levels and are not orally absorbed by infants"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [
                "Splenic rupture, including fatal cases, can occur following administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) products; evaluate for enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after administration",
                "Acute respiratory distress syndrome (ARDS) can occur; evaluate patients who develop fever and lung infiltrates or respiratory distress; discontinue in patients with ARDS",
                "Serious allergic reactions, including anaphylaxis, reported; permanently discontinue if serious allergic reaction occurs; contraindicated with history of serious allergic reaction",
                "Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving rhG-CSF products; discontinue if sickle cell crisis occurs",
                "Leukocytosis reported; monitor complete blood count; discontinue if WBC count â‰¥100x 10",
                "9",
                "/L occurs",
                "Thrombocytopenia reported; monitor platelet counts",
                "Possibly acts as growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which eflapegrastim is not approved",
                "Increased hematopoietic activity of bone marrow in response to growth factor therapy associated with transient positive bone imaging findings; consider this when interpreting bone imaging results"
            ],
            "specific": [
                {
                    "type": "Capillary leak syndrome",
                    "description": [
                        "Capillary leak syndrome reported and characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration",
                        "If symptoms occur, closely monitor and receive standard symptomatic treatment, which may include need for intensive care ",
                        "Episodes may become life-threatening if treatment delayed",
                        "Instruct patients to contact emergency services if experiencing swelling or puffiness and urinating less than usual, trouble breathing, abdominal swelling and feeling of fullness, dizziness or feeling faint, or a general feeling of tiredness"
                    ]
                },
                {
                    "type": "Glomerulonephritis",
                    "description": [
                        "Glomerulonephritis reported; generally resolves after dose reduction or discontinuation",
                        "If glomerulonephritis suspected, evaluate for cause; if causality likely, consider dose-reduction or interruption",
                        "Instruct patients to contact healthcare provider if experiencing swelling of the face or ankles, blood in urine or dark colored urine, or urinating less than usual"
                    ]
                },
                {
                    "type": "MDS and AML",
                    "description": [
                        "Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been associated with rhG-CSF products in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer",
                        "Monitor for signs and symptoms of MDS/AML in these settings",
                        "Instruct patients to contact healthcare professional if experiencing tiredness, fever, and easy bruising or bleeding"
                    ]
                },
                {
                    "type": "Aortitis",
                    "description": [
                        "Aortitis may occur as early as first week after initiating",
                        "Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (eg, C-reactive protein, WBC count)",
                        "Discontinue if aortitis suspected",
                        "Instruct patient to contact healthcare provider if experiencing fever, abdominal pain, feeling tired, or back pain"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Fatigue",
            "percent": "58"
        },
        {
            "name": "Nausea",
            "percent": "52"
        },
        {
            "name": "Diarrhea",
            "percent": "40"
        },
        {
            "name": "Bone pain",
            "percent": "38"
        },
        {
            "name": "Headache",
            "percent": "29"
        },
        {
            "name": "Pyrexia",
            "percent": "28"
        },
        {
            "name": "Anemia",
            "percent": "25"
        },
        {
            "name": "Rash",
            "percent": "25"
        },
        {
            "name": "Myalgia",
            "percent": "22"
        },
        {
            "name": "Arthralgia",
            "percent": "21"
        },
        {
            "name": "Back pain",
            "percent": "20"
        },
        {
            "name": "Decreased appetite",
            "percent": "19"
        },
        {
            "name": "Peripheral edema",
            "percent": "18"
        },
        {
            "name": "Abdominal pain",
            "percent": "17"
        },
        {
            "name": "Dizziness",
            "percent": "16"
        },
        {
            "name": "Dyspnea",
            "percent": "16"
        },
        {
            "name": "Cough",
            "percent": "15"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "14"
        },
        {
            "name": "Pain",
            "percent": "12"
        },
        {
            "name": "Pain in extremity",
            "percent": "11"
        },
        {
            "name": "Local administration reactions",
            "percent": "11"
        },
        {
            "name": "Flushing",
            "percent": "10"
        }
    ]
}